Marie Dodel
YOU?
Author Swipe
View article: P0418 The implementation of IBD-dedicated multidisciplinary healthcare pathway improves patients’ satisfaction and reduces disability in patients with IBD
P0418 The implementation of IBD-dedicated multidisciplinary healthcare pathway improves patients’ satisfaction and reduces disability in patients with IBD Open
Background The management of patients with Inflammatory Bowel Diseases (IBD) has recently evolved highlighting the need for holistic approach. We evaluated patients’ satisfaction after the implementation of an IBD-dedicated multidisciplina…
View article: P0378 Normalization or reduction of at least 50% in faecal calprotectin levels after 3 months of treatment predicts clinical and endoscopic remission at 1 year in patients with ulcerative colitis: results of the prospective MIROIR study
P0378 Normalization or reduction of at least 50% in faecal calprotectin levels after 3 months of treatment predicts clinical and endoscopic remission at 1 year in patients with ulcerative colitis: results of the prospective MIROIR study Open
Background The STRIDE-2 consensus considers the improvement of faecal calprotectin (Fcal) (biochemical response) as an intermediate goal in ulcerative colitis (UC). However, no consensual definition of biochemical response is currently ava…
View article: P0571 Transmural healing, assessed through the combination of faecal calprotectin and intestinal ultrasound, is associated with a reduced risk of bowel damage progression in patients with Crohn's disease
P0571 Transmural healing, assessed through the combination of faecal calprotectin and intestinal ultrasound, is associated with a reduced risk of bowel damage progression in patients with Crohn's disease Open
Background Faecal calprotectin (Fcal) and intestinal ultrasound (IUS) could be used as non-invasive tools to monitor Crohn's disease (CD). We evaluated the agreement between Fcal and IUS in detecting active CD and to explore the complement…
View article: P578 CDST (Clinical Decision Support Tool) is predictive of steroid-free clinical remission in patients with Crohn's disease treated with vedolizumab in a specific manner which is mainly driven by the serum level of albumin
P578 CDST (Clinical Decision Support Tool) is predictive of steroid-free clinical remission in patients with Crohn's disease treated with vedolizumab in a specific manner which is mainly driven by the serum level of albumin Open
Background The CDST (Clinical Decision Support Tool) was developed to predict response to vedolizumab in Crohn’s disease to identify a subgroup of super responders (SR). We aimed to 1) confirm that prediction of CDST is specific to vedoliz…
View article: P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study Open
Background We recently demonstrated that switching from intravenous to subcutaneous infliximab is safe and well-accepted at short-term in IBD patients including those with intensified IV regimen. However, the long-term risk of relapse in t…
View article: Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID
Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID Open
Background Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis.…
View article: DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli
DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli Open
Background Crohn’s disease (CD) is a disabling inflammatory bowel disease. Currently, the available treatments only alleviate the symptoms. The anti-TNFα represent the most efficient therapeutic class, but its mechanisms are poorly known. …